2241915-59-1

2241915-59-1 structure

Name: Anticancer agent 56
Chemical Name: Anticancer agent 56
CAS Number: 2241915-59-1
Molecular Formula: C₂₀H₁₈ClN₃O₃
Molecular Weight: 383.83
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2022-06-26 16:41:51
Modify Date: 2024-01-16 14:49:46
Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with drug-likeness properties, possessing anticancer activity against several cancer cell lines (IC50<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9[1].

Name	Anticancer agent 56

Description	Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with drug-likeness properties, possessing anticancer activity against several cancer cell lines (IC50<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Bcl-2 Family Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ROS Signaling Pathways >> Apoptosis >> Caspase
Target	IC50: 0.64 ± 0.02 μM in Leukemia RPMI-8226, 0.96 ± 0.04 μM in Leukemia SR, 0.84 ± 0.07 μM in Leukemia K-562, 0.69 ± 0.01 μM in Melanoma M14, 0.24 ± 0.01 μM in Breast MCF7, 0.26 ± 0.01 μM in Colon HCT116, 2.95 ± 0.14 μM in Prostate PC3[1]
References	[1]. Ashour HF, et al. 1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. Eur J Med Chem. 2020;189:112062.

Molecular Formula	C₂₀H₁₈ClN₃O₃
Molecular Weight	383.83